The estimated Net Worth of Rajeev Saggar is at least $2.43 Million dollars as of 19 July 2024. Rajeev Saggar owns over 1,873 units of Liquidia Corp stock worth over $2,114,539 and over the last 2 years Rajeev sold LQDA stock worth over $313,645.
Rajeev has made over 6 trades of the Liquidia Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently Rajeev sold 1,873 units of LQDA stock worth $20,846 on 19 July 2024.
The largest trade Rajeev's ever made was selling 14,887 units of Liquidia Corp stock on 15 December 2023 worth over $110,462. On average, Rajeev trades about 3,215 units every 24 days since 2022. As of 19 July 2024 Rajeev still owns at least 208,329 units of Liquidia Corp stock.
You can see the complete history of Rajeev Saggar stock trades at the bottom of the page.
Rajeev's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: